In the current study, to determine whether TEFTS inhibits tumor growth by targeting microvessels, we examined CD31 expression in glioma tissues using immunohistochemistry, but failed to find a significant difference in CD31 expression levels between TEFTS‐treated group and control group. The gene discussed is PECAM1; the disease is neoplasm.